Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.

MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo boost.

MSD’s sotatercept has become the first FDA-approved therapy for pulmonary arterial hypertension (PAH) that addresses the underlying mechanism behind the disease, rather than its symptoms. The first-in ...

Pfizer (PFE) yields 6.44% on $4,166.67 generating $268 annual income, Bristol Myers Squibb (BMY) yields 4.11% generating $171, and AbbVie (ABBV) yields 3.19% generating $133, with six pharma stocks ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

The stock market finished Friday's session modestly higher as Wall Street kicked off the month of May on an optimistic note, with oil prices retreating and corporate earnings remaining strong. The S&P ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

They may be in the same business, but Philip Morris International is a far more promising income option than Altria is at this time. Pharmaceutical giant Merck is better prepared for Keytruda’s patent ...